Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SILVER Study: ALT-711 in Isolated Systolic Hypertension
NCT00045994Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Aug 2001
- Primary completion
- Jan 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of alagebrium in isolated systolic hypertension (ISH), left ventricular hypertrophy (LVH), sponsored by Synvista Therapeutics, Inc.. Started Aug 2001; status: completed.
02
Drugs
alagebrium
03
Conditions
isolated systolic hypertension (ISH)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on NCT00045994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045994.